| Literature DB >> 33526794 |
Cristina Valero1,2,3, Mark Lee2,3, Douglas Hoen2,3, Kate Weiss2,3, Daniel W Kelly4, Prasad S Adusumilli1, Paul K Paik5, George Plitas1, Marc Ladanyi6, Michael A Postow5, Charlotte E Ariyan1, Alexander N Shoushtari5, Vinod P Balachandran1, A Ari Hakimi1,2,3, Aimee M Crago1, Kara C Long Roche1, J Joshua Smith1, Ian Ganly1,2,3, Richard J Wong1, Snehal G Patel1, Jatin P Shah1, Nancy Y Lee7, Nadeem Riaz2,3,7, Jingming Wang2,3, Ahmet Zehir6, Michael F Berger6, Timothy A Chan8,9,10, Venkatraman E Seshan11, Luc G T Morris12,13,14.
Abstract
Treatment with immune checkpoint inhibitors (ICI) has demonstrated clinical benefit for a wide range of cancer types. Because only a subset of patients experience clinical benefit, there is a strong need for biomarkers that are easily accessible across diverse practice settings. Here, in a retrospective cohort study of 1714 patients with 16 different cancer types treated with ICI, we show that higher neutrophil-to-lymphocyte ratio (NLR) is significantly associated with poorer overall and progression-free survival, and lower rates of response and clinical benefit, after ICI therapy across multiple cancer types. Combining NLR with tumor mutational burden (TMB), the probability of benefit from ICI is significantly higher (OR = 3.22; 95% CI, 2.26-4.58; P < 0.001) in the NLR low/TMB high group compared to the NLR high/TMB low group. NLR is a suitable candidate for a cost-effective and widely accessible biomarker, and can be combined with TMB for additional predictive capacity.Entities:
Year: 2021 PMID： 33526794 DOI： 10.1038/s41467-021-20935-9
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919